Publications

Export 15 results:
Sort by: Author Title Type [ Year (Desc)]
Filters: Author is Topol, Eric J  [Clear All Filters]
2012
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012;33(17):2143-50. Abstract
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012;33(17):2143-50. Abstract
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European heart journal. 2012. Abstract
2011
Berger JS, Bhatt DL, Steg GP, Steinhubl SR, Montalescot G, Shao M, et al. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2011;162(1):98-105.e1. Abstract
Hankey GJ, Johnston CS, Easton DJ, Hacke W, Mas J-, Brennan D, et al. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke. 2011;6(1):3-9. Abstract
Weber M, Bhatt DL, Brennan DM, Hankey GJ, Steinhubl SR, Johnston CS, et al. High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart. 2011;97(8):626-31. Abstract
2010
Berger PB, Bhatt DL, Fuster V, Steg GP, Fox KA, Shao M, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: Results from the (CHARISMA) trial. Circulation. 2010;121(23):2575-83. Abstract
Topol EJ, Bousser M-, Fox KA, Creager MA, Despres J-, Easton DJ, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010;376(9740):517-23. Abstract
Hankey GJ, Hacke W, Easton DJ, Johnston CS, Mas J-, Brennan DM, et al. Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Stroke. 2010;41(8):1679-83. Abstract
2009
Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak K-, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone [CHARISMA] trial). Am J Cardiol. 2009;103(10):1359-63. Abstract
Collet J-, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Hu T, et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis. 2009;102(6-7):485-96. Abstract
Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg GP, Montalescot G, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation. 2009;120(23):2337-44. Abstract
Mak K-, Bhatt DL, Shao M, Hankey GJ, Easton DJ, Fox KA, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J. 2009;157(4):658-65. Abstract
Mak K-, Bhatt DL, Shao M, Haffner SM, Hamm CW, Hankey GJ, et al. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J. 2009;30(7):857-65. Abstract
2008
Hart RG, Bhatt DL, Hacke W, Fox KA, Hankey GJ, Berger PB, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovascular diseases (Basel, Switzerland). 2008;25:344-7. Abstract